There were massive moves from US tech stocks overnight which added a whopping $291.66 billion in combined market valuation. Meanwhile, AstraZeneca jumped to a record after results from a vaccine trial were published, yet faded after analysts said the data, while good, weren’t as stellar as hoped for. Abhilash Narayan, Senior Investment Strategist, Standard Chartered Private Bank breaks down all this and more on The Bigger Picture. 

<p>There were massive moves from US tech stocks overnight which added a whopping $291.66 billion in combined market valuation. Meanwhile, AstraZeneca jumped to a record after results from a vaccine trial were published, yet&nbsp;faded after analysts said the data, while good, weren&rsquo;t as stellar as hoped for. <strong>Abhilash Narayan, Senior Investment Strategist, Standard Chartered Private Bank&nbsp;</strong>breaks down all this and more on The Bigger Picture.&nbsp;</p>

Advertisement